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Abstract
Elevation of the interstitial fluid pressure (IFP) of carcinoma is an obstacle in treatment of tumors by chemotherapy and
correlates with poor drug uptake. Previous studies have shown that treatment with inhibitors of platelet-derived growth
factor (PDGF) or vascular endothelial growth factor (VEGF) signaling lowers the IFP of tumors and improve chemotherapy. In
this study, we investigated whether the combination of PDGFR and VEGFR inhibitors could further reduce the IFP of KAT-4
human carcinoma tumors. The tumor IFP was measured using the wick-in-needle technique. The combination of STI571 and
PTK/ZK gave an additive effect on the lowering of the IFP of KAT-4 tumors, but the timing of the treatment was crucial. The
lowering of IFP following combination therapy was accompanied by vascular remodeling and decreased vascular leakiness.
The effects of the inhibitors on the therapeutic efficiency of Taxol were investigated. Whereas the anti-PDGF and anti-VEGF
treatment did not significantly inhibit tumor growth, the inhibitors enhanced the effect of chemotherapy. Despite having an
additive effect in decreasing tumor IFP, the combination therapy did not further enhance the effect of chemotherapy.
Simultaneous targeting of VEGFR and PDGFR kinase activity may be a useful strategy to decrease tumor IFP, but the timing
of the inhibitors should be carefully determined.
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Introduction
The development of tissue stroma is controlled by several
growth factors and cytokines. Platelet-derived growth factor
(PDGF) is particularly important for proliferation and chemotaxis
of connective tissue cells (reviewed in [1]). PDGF is a family of
homo- and hetero-dimeric molecules of structurally related A-, B-,
C- and D-polypeptide chains, which exert their cellular effects by
binding to a- and b-tyrosine kinase receptors. Vascular endothelial
growth factor (VEGF) is the prototype of a five-membered family
which control angiogenesis and lymphangiogenesis; the VEGF
isoforms also act via tyrosine kinase receptors, i.e. the VEGF
receptor 1, 2 and 3 [2].
Solid tumors often have an increased interstitial fluid pressure
(IFP) which perturbs transcapillary transport and thus is an
obstacle in tumor treatment with chemotherapy [3]. The reasons
for the increased tumor IFP include leakiness of tumor vessels, e.g.
as a consequence of overexpression of VEGF [4], which has a well-
characterized vascular permeability effect. Administration of the
anti-VEGF antibody bevacizumab to patients with colorectal
cancer decreased IFP and vessel leakiness [5]. Moreover,
overexpression of PDGF can also contribute to increased IFP of
tumors, since PDGF inhibition decreases tumor IFP [6]. In normal
tissues, PDGF regulates interstitial fluid pressure [7] by acting on
stromal fibroblasts and causing an integrin-mediated contraction
of the cells that affects the extracellular matrix [8]. Since treatment
with either VEGF antagonists [5,9,10] or PDGF antagonists
[6,11,12] have been found to lower tumor IFP, and in view of the
potential clinical utility of lowering tumor IFP to enhance
chemotherapy, we investigated if the combination of anti-VEGF
and anti-PDGF treatment gives a synergistic lowering effect on
tumor IFP.
Results
Combination of PDGF and VEGF Receptor Kinase
Inhibitors Lowers Tumor IFP
KAT-4 tumors were grown subcutaneously in SCID mice. We
used the low molecular weight compound imatinib (Glivec,
STI571) as a PDGF receptor tyrosine kinase inhibitor at
100 mg/kg body weight. As a VEGF receptor kinase inhibitor,
we used PTK/ZK at 25 mg/kg body weight; at this concentration
PTK/ZK inhibits the VEGF receptor kinases, but has minimal
effects on other kinases such as the PDGF receptor kinases [13].
Consistent with our previous findings [11], treatment with
STI571 for 4 days lowered the IFP of KAT-4 tumors (Fig. 1).
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lowered the tumor IFP. Moreover, the combination of STI571
treatment for 4 days and PTK/ZK treatment for the last 2 of these
days (termed short term combination treatment) gave an additive
effect, whereas treatment with both STI571 and PTK/ZK for the
full 4 days (termed long term combination treatment) gave a result
similar to vehicle treatment (Fig. 1).
Combination Treatment Affects Tumor Vascularization
To investigate the effect of anti-PDGF and anti-VEGF treatment
on tumor vascularization, tumor sections were stained with CD31
antiserum to visualize endothelial cells, followed by stereological
analysis. Upon short term, but not long term, combination
treatment, the number of vessels decreased (Fig. 2A, Fig. S1).
STI571 given for four days decreased the total vessel area and the
vessel perimeter, as did the 4 day treatment with PTK/ZK as well
as long and short term combination treatment (Fig. 2B,C, Fig. S1).
Despite lowering IFP, PTK/ZK given for two days had no effect on
the vessel number and morphology (Fig. 2, Fig. S1).
Anti-Angiogenic Therapy Affects Pericyte Coverage of
Vessels
We also determined the effect of combination treatment on the
coverage of vessels by desmin-positive pericytes [14]. Both the
number of desmin-positive pericytes per perimeter (Fig. 3A, Fig.
S1) and the number of desmin-positive pericytes per vessel (Fig. 3B)
were decreased upon treatment with PTK/ZK for 4 days, as well
as with both combination treatments. Also, the number of desmin-
positive pericytes per vessel was lowered following treatment with
STI571 (Fig. 3B, Fig. S1).
Enhanced Tumor Cell Apoptosis
To determine the effect of the therapies on tumor cell apoptosis
and proliferation, tumor sections were stained with antibodies
recognizing cleaved caspase-3 and Ki67, respectively. As seen in
Fig. 4A and in Fig. S2, no effect was observed by any of the
treatments on tumor cell proliferation. On the other hand, both
monotherapies with STI571 or PTK/ZK for 4 days, as well as
both short-term and long-term combination therapy enhanced
apoptosis of tumor cells (Fig. 4B, Fig. S3).
Effect of Anti-PDGF and Anti-VEGF Treatment on Vascular
Leakage
The effect of PDGF and VEGF receptor inhibitors on tumor
vessel leakiness was determined by injection of Evans blue, a dye
that quantitatively binds to albumin in the circulation. The
Figure 1. Combination of PDGF and VEGF receptor kinase
antagonists lowers tumor IFP. Mice with KAT-4 tumors grown
subcutaneously were treated with vehicle, STI571, PTK/ZK, or with
combinations of STI571 and PTK/ZK. The IFP of the tumors were
measured by the wick-in-needle technique. Data are presented as
means +/2 SEM. Statistically significant differences (p,0.05) compared
to vehicle and long term combination treatment (*), and to all groups
(#) are indicated.
doi:10.1371/journal.pone.0008149.g001
                 
   
 
 
                 
   
   
   
 
 
                 








Figure 2. Effects of PDGF and VEGF receptor kinase inhibitors
on tumor vascularization. Sections of KAT-4 tumors from mice
treated with vehicle, STI571 or PTK/ZK, alone or in combination were
stained for endothelial cells of blood vessels by CD31 antibodies and
then subjected to stereological analysis. Data are presented as means
+/2 SEM. Asterisks indicate statistically significant differences (p,0.05)
compared to control (vehicle treatment).
doi:10.1371/journal.pone.0008149.g002
RTK Antagonists and Tumor IFP
PLoS ONE | www.plosone.org 2 December 2009 | Volume 4 | Issue 12 | e8149tumor vessel leakage was quantified by dye extraction from
excised tumors. Treatment of KAT-4 tumor-bearing mice
with VEGF receptor inhibitor alone or in combination with
PDGF receptor inhibitor significantly lowered vessel leakiness
(Fig. 5). This effect was not observed after treatment by STI571
alone.
Effect of Anti-PDGF and Anti-VEGF Treatment on
Extracellular Volume and Plasma Volume
The extracellular volume (ECV) and plasma volume (PV) of
tumor and skin were determined by the dilution of
51Cr-EDTA
and
125I-labeled serum albumin, respectively. The ECV of tumor,
as well as skin, was significantly elevated after 4 days of treatment
with STI571 (Table 1), whereas treatment with PTK/ZK alone
had no significant effect on ECV of tumors or skin. The short term
combination treatments had no significant effect on the total tissue
water, ECV and PV of the tumor, but it increased both PV and
ECV in the skin (Table 1). The long term combination treatment
increased the mean tumor ECV, but with large variations within
the group, suggesting that vasculature may be undergoing
functional remodeling.
Effect of Anti-PDGF and Anti-VEGF Treatment on the
Effect of Chemotherapy
When mice inoculated with KAT-4 tumors were treated with
STI571 or PTK/ZK, alone or in combination, no significant
effect on tumor growth was observed (Fig. 6A). Likewise, when the
animals were treated with Taxol at a concentration of 5 mg/kg,
no significant effect on tumor growth was observed. However,
when Taxol treatment was combined with STI571 and PTK/ZK,
alone or in combination, the tumor growth were reduced (Fig. 6B).
The group treated with STI571 together with Taxol had
significantly reduced growth rate compared to the group treated
with Taxol only, and to the group treated with PTK/ZK together
with Taxol. Combination of STI571 and PTK/ZK, either
continuously or intermittently for four and two days before the
                          
         
 
   
 
                          
         
   
   
 
 
Figure 3. Effect of PDGF and VEGF receptor kinase inhibitors
on desmin-positive pericyte coverage. Sections of KAT-4 tumors
from mice treated with vehicle, STI571 or PTK/ZK, alone or in
combination were stained with antibodies against the pericyte marker
desmin. The number of desmin-positive pericytes per vessel perimeter
(panel A) or per number of vessels (panel B) were quantified. Data are
presented as means +/2 SEM. Statistically significant differences
(p,0.05) compared to control (vehicle treatment;*), compared to
PTK/ZK 2 days (#), and compared to STI571 4 days (1), are indicated.
doi:10.1371/journal.pone.0008149.g003
Figure 4. Effect of PDGF and VEGF receptor kinase inhibitors
on KAT-4 tumor cell proliferation and apoptosis. Sections of KAT-
4 tumors from mice treated with vehicle, STI571 or PTK/ZK, alone or in
combinations, were stained for Ki67 (panel A) and cleaved caspase-3
(panel B) to monitor proliferation and apoptosis, respectively. Data are
presented as means +/2 SEM. Statistically significant differences
(p,0.05) compared to control (vehicle treatment;*), and compared to
PTK/ZK 2 days (#), are indicated.
doi:10.1371/journal.pone.0008149.g004
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compared to monotreatment (Fig. 6B).
Discussion
Previous studies have shown that anti-PDGF treatment lowers
the IFP of tumors [6] and improves the effect of chemotherapy
[11]. Since both STI571 and the more specific PDGF aptamers
exerted similar effects in KAT-4 tumors on regulation of IFP and
Taxol treatment efficiency [11], the observed effects of STI571 are
likely to be mediated by inhibition of PDGFR. The effect is
presumably mediated by a relaxation of connective tissue cells,
which participate in the control of tissue IFP by integrin-mediated
contacts with extracellular matrix fibers [8]. It is also possible that
anti-PDGF treatment results in a rebuilding of the extracellular
matrix of the stroma into a less dense structure allowing a
reduction of IFP [15]. However, STI571 inhibits also other kinases
such as the stem cell factor receptor, Abl, Arg [16] and DDR1
[17]; therefore, although unlikely, one cannot exclude the
possibility that inhibition of these pathways contributed to the
lowering of the IFP. In addition, anti-VEGF treatment has also
been shown to lower tumor IFP [5,9,10]. Since VEGF has a well-
characterized vascular permeability effect, it is likely that anti-
VEGF lowers tumor IFP by lowering vessel leakiness and thereby
lowering the colloid osmotic pressure of the interstitium of tumors.
Thus, anti-PDGF and anti-VEGF treatment most likely affect
tumor IFP by different mechanisms. We therefore explored the
possibility that the combination of anti-PDGF and anti-VEGF
treatment would give an additive effect. Our results indeed show
that the combination treatment gives a more efficient lowering of
the IFP of the human carcinoma KAT-4 grown subcutaneously in
SCID mice. This effect is most likely due to the additive effect of
tumor stroma relaxation and decreased plasma protein leakage. In
addition, anti-VEGFR therapy has been suggested to normalize the
tumor vasculature, thereby temporarily improving their function
[18] which might cause improved delivery of the PDGFR inhibitor.
A notable observation was, however, that the timing of the anti-
VEGF treatment was of importance when given in combination
with anti-PDGF treatment. Thus, two days of treatment efficiently
lowered tumor IFP, but not four days of treatment (Fig. 1). The
reason for this finding is not clear, but may be related to a transient
vessel normalization after anti-VEGF administration followed by a
deterioration of the vessels [18]. The decreased functionality of the
vessels upon prolonged anti-VEGF treatment could then be
accompanied by a decreased delivery of PDGF receptor inhibitor.
Although both short and long term combination therapy
decreased vessel leakiness (Fig. 5) only short term combination
treatment gave a more pronounced anti-angiogenic effect (Fig. 2,
Fig. S1) and decreased pericyte coverage (Fig. 3, Fig. S1),
compared to long term combination treatment and to the
monotherapies.
We have previously shown that treatment with bevacizumab
lowers protein leakage as well as ECV in KAT-4 carcinoma [10],
whereas in the present study mono-treatment with PTK/ZK had
effect only on plasma protein leakage but not ECV. This
discrepancy could at least partly depend on the fact that the
processes studied are transient, and that there are pharmacokinetic
differences between treatment with monoclonal antibodies and
low molecular weight inhibitors. In addition, PTK/ZK at high
concentrations also targets other kinases including PDGFR [19].
We therefore used a modest concentration of PTK/ZK to avoid
inhibition of PDGFR [13]. It is possible that those modest
concentrations of PTK/ZK did not correct vessel leakiness equally
efficient as treatment with bevacizumab.
Figure 5. Effect of PDGF and VEGF receptor kinase inhibitors
on vessel leakage. Evans blue was injected into the blood stream of
tumor bearing mice. The dye in the tumor tissue was extracted and
determined spectrophotometrically at 600 nm. The result was present-
ed as the amount of Evans blue [4] extracted from dry weight of the
tumor tissue (mg) and divided by the amount of Evans blue [4] present
in the 1 ml of serum. Data are presented as means +/2 SEM. Statistically
significant differences (p,0.05) compared to vehicle treatment (*) are
indicated.
doi:10.1371/journal.pone.0008149.g005
Table 1. Extracellular volume (ECV), plasma volume (PV) and total tissue water (TTW) measured in the animals treated with either














PBS (n=10) 4.75660.668 0.04160.019 1.61260.451 1.94460.406 0.00860.005 1.35760.430




PTK/ZK 4d (n=8) 4.97760.538 0.05260.033 1.53360.311 2.57360.744 0.01860.012 1.61460.422
PTK/ZK 2d/STI571 4d (n=7) 4.65860.876 0.15660.250 1.51560.481 3.12261.279 0.11060.106
* 2.39961.097
*
PTK/ZK 4d/STI571 4d (n=6) 5.18760.789 0.04660.026 2.14060.587 2.34860.672 0.01660.006 1.70460.527
All results are presented as mean and S.E.M. Analysis of statistical significance was evaluated with 1-way ANOVA followed by the post-hoc Dunn’s test.
*p,0.05 compared to PBS treatment.
1p,0.05 compared to PBS treatment when removing the highest outlying data point in PTK/ZK 2d/STI571 4d treatment group.
doi:10.1371/journal.pone.0008149.t001
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transiently lowers IFP, increase transport of low molecular weight
tracers and of 5-fluorouracil through the tumors as quantified by
microdialysis, increases the efficiency of chemotherapy and
increases the extracellular volume [20,21]. An increase in
extracellular volume greatly increases hydraulic conductivity
through tissues, in fact hydraulic conductivity increases exponen-
tially to a volume increase [22]. The present finding that treatment
with STI571 increases the extracellular volume in KAT-4
carcinoma is thus likely to in part explain the additive effect of
STI571 to chemotherapy; transport of the chemotherapeutic
agents would be facilitated when the extracellular volume
increases. Indeed, in previous studies we have shown that
transport of low molecular weight tracer through experimental
PROb colorectal rat carcinoma quantified by microdialysis is
increased after treatment with STI571 [6]. This is also indicated
by our data showing that treatments resembling the protocols
resulting in an increased extracellular volume, i.e. STI571 for 4
days, or show a trend to such an increased extracellular volume,
i.e. PTK/ZK for 4 days together with STI571 for 4 days, gave the
greatest effects with regard to promoting the anti-tumor effects of
Taxol. The failure of the intermittent combination therapy to
further potentiate the effect of Taxol could be due to that the
decreased vessel leakiness (Fig. 5) prevented an increase in the
ECV, thereby inhibiting fluid convection [23]. Further studies are
needed to determine the optimal timing of the delivery of the
various inhibitors to lower IFP and increase the fluid convection in
order to potentiate chemotherapy. Our data suggest that
combination treatment with anti-PDGFR and anti-VEGFR
tyrosine kinase inhibitors can be used to efficiently lower the IFP
of KAT-4 tumors, but that the timing appears to be crucial.
Whereas the monotherapies improved the therapeutic effect of




The human carcinoma KAT-4 (American Type Culture
Collection) was used in this study. KAT-4 cells were originally
described as thyroid cancer cells [24], but have recently been
shown to resemble the human colorectal adenocarcinoma cell line
HT-29 and a thyroid origin of the KAT-4 carcinoma has been
questioned [25]. Cells were cultured in RPMI 1640 medium
(Sigma) supplemented with 10% fetal bovine serum and antibiotics
(100 U/ml penicillin and 100 mg/ml streptomycin). Cultured
KAT-4 cells produce and release a non-heparin binding isoform
of VEGF-A [10].
Antibodies
Goat anti-mouse CD31/PECAM-1 antibody was obtained
from SantaCruz Biotechnology (Santa Cruz, CA), monoclonal
antibodies against Ki67 (TEC3) and desmin were from DAKO
(Glostrup, Denmark), and a rabbit polyconal antiserum against
cleaved caspase-3 from Cell Signaling Technology (Denvers, MA).
Tumor Growth and Treatment
Animal experiments were approved by the local ethics
committees at the universities in Bergen and Uppsala, and
performed according to the UKCCCR guidelines [26]. All
manipulations were performed under isoflurane (Abbott Scandi-
navia, Solna, Sweden) gas anesthesia. Six to eight week-old Fox
Chase SCID mice (M&B, Ry, Denmark) received subcutaneous
inoculation in the dorsal skinfold of 2610
6 KAT-4 cells suspended
in 100 mL of PBS. Tumor length and width were measured using
calipers, and tumor volume was calculated as p/66
length6width6width. When the tumor volume reached
400 mm
3 for IFP measurements, mice were randomized to receive
p.o. gavage of either vehicle (1% Tween 80, 5% DMSO),
100 mg/kg/day STI571 for 4 days, 25 mg/kg/day PTK/ZK
either for 2 days or for 4 days, or 100 mg/kg/day STI571 together
with 25 mg/kg/day PTK/ZK for 4 days (termed long term
combination treatment) or 100 mg/kg/day STI571 for 4 days
followed with 25 mg/kg/day PTK/ZK for last 2 days (termed
short term combination treatment). Inhibitors were provided by
Novartis Pharma AG, Basel, Switzerland. In the Taxol study,
when the tumor volume reached 100 mm
3 mice were given
vehicle, STI571 or PTK/ZK alone for 21 days. Additionally,
STI571 was combined with PTK/ZK daily (named continuous
treatment) or STI571 was given for 4 days in combination with
PTK/ZK for the last 2 days prior to Taxol injection (named
intermittent treatment). Taxol (Bristol-Myers Squibb AB, Sweden)
Figure 6. Effect of the combination of chemotherapy, and
PDGF and VEGF receptor kinase inhibitors on tumor growth.
KAT-4 tumor cells were inoculated subcutaneously in mice which then
were treated with daily doses of STI571 or PTK/ZK or both (panel A). B.
Taxol (5 mg/kg) was given every five days in combination with daily
doses of STI571 or PTK/ZK, alone or in combination (continuous
treatment) Alternatively, STI571 was given for four days in combination
with PTK/ZK for the last two days prior to Taxol injection (intermittent
treatment). Data are presented as means +/2 SEM. Statistically
significant differences (p,0.05) compared to control (vehicle+Taxol
treatment; *) or STI571+Taxol vs PTK/ZK+Taxol (panel B; #), are
indicated.
doi:10.1371/journal.pone.0008149.g006
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schedule. Animals were euthanized by intraperitoneal injection of
90 mg/kg pentobarbitone. Tumors were subsequently removed
surgically, weighed and fixed in 4% paraformaldehyde overnight.
Measurement of Tumor IFP
Tumor IFP was measured by the wick-in-needle technique, as
described previously [6,20]. Briefly, a standard 23-gauge needle
filled with nylon floss and saline, supplemented with 50 IE/mL of
heparin, was inserted into the centre of the tumor and connected
to a pressure transducer for a period of 30 min. This setup enables
stable and continuous recording of fluid pressure. The catheter
was clamped during the measurement to verify that the pressure
returned to the initial value with a deviation of no more than
1 mmHg. Tumor IFP was measured earliest 4 h after the last
administration of vehicle, STI571, PTK/ZK or combinations of
both drugs. IFP was measured at two separate locations in the
tumor and the mean was calculated for each tumor. There was no
difference in the growth rate among the groups at the day of
measurement (data not shown).
Immunohistochemistry and Stereological Analyses of
Tumor Vessels
Excised tumors were embedded in paraffin, and 4 mm thick
sections were cut onto Superfrost Plus slides (Histolab, Gothen-
burg, Sweden). The sections were deparaffinized and boiled in
10 mM citrate buffer, pH 6.0 for 267 min at 750 W in a
microwave oven. Tissue peroxidase activity was quenched by
incubation with 3% H2O2 in PBS for 10 min, and unspecific
antibody binding was blocked by incubation with 20% serum
species-matched to the secondary antibody. Endothelial cells were
stained with a CD31/PECAM-1 antibody (4 mg/mL), and a
desmin antibody was used to stain pericytes (1:50). Antibodies
against cleaved caspase-3 (1:200) and Ki-67 (1:25) were used to
stain for apoptotic and proliferative cells, respectively. The fraction
of cleaved caspase-3 positive cells or Ki67 positive cells was
determined after analyzing 1,000 cells. For pericyte quantification,
the number of pericyte nuclei associated with tumor vessels was
counted. Omission of primary antibody was used as a negative
control. Positive reactions were developed using DAB (Vector
Laboratories, Inc., Burlingame, CA) as a peroxidase substrate.
Sections were counterstained in Mayer’s hematoxylin, dehydrated,
and coverslipped in Mountex resin (Histolab, Gothenburg,
Sweden). Stereological quantification of capillary tumor blood
vessels was performed after CD31 staining. Vision fields were
selected by screening tumor sections every 1 mm. Images of the
vision fields (0.09 mm
2) were captured, blood vessels and viable
area were manually marked and vessel area and vessel perimeter
was quantified using digital image processing and analysis software
‘‘Leica QWin Standard’’ in 9–40 vision fields (depending on the
size of the sections) of one section from each animal.
Determination of Extracellular and Plasma Volumes
Extracellular volume (ECV) and plasma volume (PV) in tumor
and skin were determined by the dilution principle using
radioactive-labelled isotopes [10]. Total tissue water (TTW) was
determined as (wet weight-dry weight)/dry weight. Tissue samples
were dried at 50uC until constant weight (normally 3–4 weeks).
The distribution volumes for
51Cr-EDTA (Institute of Energy
Technology, Kjeller, Norway) and
125I-labeled human serum
albumin (
125I-HAS); Institute of Energy Technology, Kjeller,
Norway), measuring ECV and PV respectively, were calculated as
plasma equivalent volumes, i.e. counts per min per mg of tissue
divided by counts per min per ml of plasma. Both isotopes were
given after functional nephrectomy by the bilateral ligation of the
renal pedicles via flank incision.
51Cr-EDTA (300,000 cpm in
0.2 mL PBS) was injected into the catheter in the tail vein and left
to circulate for 85 min before injecting
125I-HAS (3610
6 cpm in
0.2 mL PBS). Blood samples were taken 5 min later, by heart
puncture. Skin from the back was used as a reference control.
Radioactivity was determined in a COBRA II, Auto-gamma
counter (Packard) with automatic background and spillover
correction.
Vascular Leakage Assay
Evans blue (30 mg/kg) was administered via tail vein injection
30 minutes before sacrifice. Tumors were excised, dried at 60uC
over-night and weighed, followed by extraction in 1 mL
formamide at 55uC over night, and the content was quantified
by reading at 600 nm in a spectrophotometer [27]. Additionally,
blood samples were taken and the amount of Evans blue in the
tumor was related to the amount of the Evans blue in the serum.
Statistical Methods
Statistical analysis of the IFP measurements and tumor growth
assays were analyzed with One-way analysis of variance, with a
subsequent post hoc analysis with Duncan’s adjustment. The
experiments determining the total tissue water, extracellular
volume and plasma volume were analyzed with Kruskall-Wallis
One Way Analysis on Ranks when the normality test failed with a
subsequent post hoc analysis using Dunn’s test. P,0.05 was
considered statistically significant.
Supporting Information
Figure S1 Effects of PDGF and VEGF receptor kinase inhibitors
on vessel morphology and pericyte coverage. Four A ˆmm thick
sections of KAT-4 tumors from mice treated with vehicle, STI571
or PTK/ZK, alone or in combination, were stained for
endothelial cells of blood vessels by CD31 antibodies and for
pericytes by desmin antibodies. Endothelial cells are stained dark
blue with alkaline phosphatase and the pericytes are stained brown
using DAB as peroxidase substrate. Tumor cells are counter-
stained with hematoxylin. The bars represent 20 A ˆmm. (A) vehicle,
(B) STI571 4 days, (C) PTK/ZK 2d, (D) PTK/ZK 4d, (E) STI571
4d and PTK/ZK 2d, (F) STI571 4d and PTK/ZK 4d. Arrows
point at desmin positive pericytes and arrowheads at CD31
positive endothelial cells. The areas within red squares were
enlarged and put on top of the original photos.
Found at: doi:10.1371/journal.pone.0008149.s001 (3.06 MB EPS)
Figure S2 Effect of PDGF and VEGF receptor kinase inhibitors
on KAT 4 tumor cell proliferation. Sections of KAT 4 tumors
from mice treated with vehicle, STI571 or PTK/ZK, alone or in
combinations, were stained for Ki67 to monitor tumor cell
proliferation. Ki67 positive cells are stained brown using DAB as
peroxidase substrate. Tumor cells are counterstained with
hematoxylin. The bars represent 20 A ˆmm. (A) vehicle, (B)
STI571 4d, (C) PTK/ZK 2d, (D) PTK/ZK 4d, (E) STI571 4d
and PTK/ZK 2d, (F) STI571 4d and PTK/ZK 4d. Arrows point
at Ki67 positive cells.
Found at: doi:10.1371/journal.pone.0008149.s002 (2.17 MB TIF)
Figure S3 Effect of PDGF and VEGF receptor kinase inhibitors
on KAT 4 tumor cell apoptosis. Sections of KAT 4 tumors from
mice treated with vehicle, STI571 or PTK/ZK, alone or in
combinations, were stained for cleaved caspase-3 to monitor
tumor cell apoptosis. Cleaved caspase-3 positive cells are stained
RTK Antagonists and Tumor IFP
PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8149brown using DAB as peroxidase substrate. Tumor cells are
counterstained with hematoxylin. The bars represent 20 mm. (A)
vehicle, (B) STI571 4d, (C) PTK/ZK 2d, (D) PTK/ZK 4d, (E)
STI571 4d and PTK/ZK 2d, (F) STI571 4d and PTK/ZK 4d.
Arrows point at cleaved caspase-3 positive cells.
Found at: doi:10.1371/journal.pone.0008149.s003 (2.17 MB TIF)
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